NASDAQ:SNSE Sensei Biotherapeutics (SNSE) Stock Forecast, Price & News $1.46 0.00 (0.00%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$1.46▼$1.5550-Day Range$1.31▼$1.8152-Week Range$1.28▼$2.39Volume13,317 shsAverage Volume20,748 shsMarket Capitalization$45.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Sensei Biotherapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.95% of Float Sold ShortDividend StrengthN/ASustainability-0.38Upright™ Environmental ScoreNews Sentiment0.56Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.31) to ($1.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector1233rd out of 1,980 stocksPharmaceutical Preparations Industry617th out of 978 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Sensei Biotherapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.95% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sensei Biotherapeutics has recently decreased by 15.46%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSensei Biotherapeutics has received a 77.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sensei Biotherapeutics is -0.38. Previous Next 2.0 News and Social Media Coverage News SentimentSensei Biotherapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sensei Biotherapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for SNSE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders19.90% of the stock of Sensei Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.59% of the stock of Sensei Biotherapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sensei Biotherapeutics are expected to decrease in the coming year, from ($1.31) to ($1.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sensei Biotherapeutics (NASDAQ:SNSE) StockSensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Read More Receive SNSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SNSE Stock News HeadlinesJune 1, 2023 | finance.yahoo.comSensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid TumorsMay 31, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceJune 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 10, 2023 | markets.businessinsider.comCitigroup Remains a Buy on Sensei Biotherapeutics (SNSE)May 9, 2023 | finance.yahoo.comSensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsApril 23, 2023 | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Shares Down 16.6% April 20, 2023 | finance.yahoo.comSensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking AntibodyApril 18, 2023 | finance.yahoo.comSensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023June 2, 2023 | Edge On The Street (Ad)How to Invest in AI's Fast-Growing MarketThe AI market stands at $160 billion in 2023. Estimates are the AI market will grow 20-fold to $1.8 TRILLION by 2030. One little-known company is looking to win big with a new network technology no one else has. AI could explode... and soon.April 13, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual ConferenceMarch 31, 2023 | americanbankingnews.comSensei Biotherapeutics (NASDAQ:SNSE) Posts Quarterly Earnings ResultsMarch 31, 2023 | americanbankingnews.comSensei Biotherapeutics, Inc. (NASDAQ:SNSE) to Post Q1 2023 Earnings of ($0.35) Per Share, Oppenheimer ForecastsMarch 30, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual SymposiumMarch 28, 2023 | finance.yahoo.comSensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business HighlightsMarch 21, 2023 | finance.yahoo.comSensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking AntibodyMarch 14, 2023 | finance.yahoo.comSensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023March 7, 2023 | finance.yahoo.comSensei Biotherapeutics Adopts Stockholder Rights AgreementMarch 6, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare ConferenceFebruary 21, 2023 | finance.yahoo.comSensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody TherapeuticsFebruary 16, 2023 | technews.tmcnet.comSensei Biotherapeutics to Participate in Citi's 2023 Virtual Oncology Leadership SummitFebruary 16, 2023 | finance.yahoo.comSensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership SummitFebruary 14, 2023 | finance.yahoo.comSensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody TherapeuticsFebruary 6, 2023 | msn.comSensei in agreement with National Cancer Institute for solid tumors candidateFebruary 6, 2023 | finance.yahoo.comSensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking AntibodyJanuary 5, 2023 | markets.businessinsider.comSensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For LibtayoJanuary 5, 2023 | finance.yahoo.comSensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo® (cemiplimab) in Solid TumorsDecember 12, 2022 | technews.tmcnet.comNewman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)See More Headlines SNSE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNSE Company Calendar Last Earnings3/28/2023Today6/02/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNSE CUSIPN/A CIK1829802 Webwww.senseibio.com Phone240-243-8000FaxN/AEmployees56Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.32% Return on Assets-37.60% Debt Debt-to-Equity Ratio0.01 Current Ratio13.00 Quick Ratio13.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book0.48Miscellaneous Outstanding Shares30,980,000Free Float24,816,000Market Cap$45.08 million OptionableNot Optionable Beta-0.18 Key ExecutivesMr. John K. Celebi M.B.A. (Age 50)MBA, Pres, CEO & Director Comp: $792.98kMs. Erin Colgan (Age 41)Chief Financial Officer Comp: $453.19kDr. Steven A. FullerChief Biopharmaceuticals Devel. OfficerDr. Edward Van der Horst Ph.D.Chief Scientific OfficerMs. Lora PikeVP of Investor Relations & CommunicationsMr. Christopher Gerry J.D.VP & Gen. CounselMr. Patrick Stephen Gallagher M.B.A.M.P.H., Chief Bus. OfficerMore ExecutivesKey CompetitorsEnlivex TherapeuticsNASDAQ:ENLVMEI PharmaNASDAQ:MEIPCoya TherapeuticsNASDAQ:COYANextCureNASDAQ:NXTCSELLAS Life Sciences GroupNASDAQ:SLSView All CompetitorsInsiders & InstitutionsTwo Sigma Advisers LPSold 9,100 shares on 5/15/2023Ownership: 0.085%Renaissance Technologies LLCSold 47,354 shares on 5/12/2023Ownership: 0.404%Bank of America Corp DEBought 41,305 shares on 5/12/2023Ownership: 0.291%Apeiron Investment Group Ltd.Bought 2,200 shares on 2/23/2023Total: $3,542.00 ($1.61/share)View All Insider TransactionsView All Institutional Transactions SNSE Stock - Frequently Asked Questions Should I buy or sell Sensei Biotherapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNSE shares. View SNSE analyst ratings or view top-rated stocks. How have SNSE shares performed in 2023? Sensei Biotherapeutics' stock was trading at $1.49 at the start of the year. Since then, SNSE stock has decreased by 2.3% and is now trading at $1.4550. View the best growth stocks for 2023 here. Are investors shorting Sensei Biotherapeutics? Sensei Biotherapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 154,800 shares, a drop of 15.5% from the April 30th total of 183,100 shares. Based on an average daily trading volume, of 79,100 shares, the short-interest ratio is currently 2.0 days. Currently, 1.0% of the shares of the company are sold short. View Sensei Biotherapeutics' Short Interest. When is Sensei Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our SNSE earnings forecast. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) announced its earnings results on Tuesday, March, 28th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.01. When did Sensei Biotherapeutics IPO? (SNSE) raised $100 million in an IPO on Friday, February 5th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. served as the underwriters for the IPO. What is Sensei Biotherapeutics' stock symbol? Sensei Biotherapeutics trades on the NASDAQ under the ticker symbol "SNSE." Who are Sensei Biotherapeutics' major shareholders? Sensei Biotherapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.40%), Bank of America Corp DE (0.29%) and Two Sigma Advisers LP (0.08%). Insiders that own company stock include Apeiron Investment Group Ltd, Cambrian Biopharma Inc, James Peyer, Robert Hamilton Pierce and Thomas G Ricks. View institutional ownership trends. How do I buy shares of Sensei Biotherapeutics? Shares of SNSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sensei Biotherapeutics' stock price today? One share of SNSE stock can currently be purchased for approximately $1.46. How much money does Sensei Biotherapeutics make? Sensei Biotherapeutics (NASDAQ:SNSE) has a market capitalization of $45.08 million. The company earns $-48,590,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. How can I contact Sensei Biotherapeutics? Sensei Biotherapeutics' mailing address is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. The official website for the company is www.senseibio.com. The company can be reached via phone at 240-243-8000 or via email at ir@senseibio.com. This page (NASDAQ:SNSE) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.